Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.

PubWeight™: 1.11‹?› | Rank: Top 10%

🔗 View Article (PMC 3180562)

Published in Cancer Chemother Pharmacol on June 17, 2011

Authors

Yosuke Togashi1, Katsuhiro Masago, Masahide Fukudo, Yasuhiro Tsuchido, Chiyuki Okuda, Young Hak Kim, Yasuaki Ikemi, Yuichi Sakamori, Tadashi Mio, Toshiya Katsura, Michiaki Mishima

Author Affiliations

1: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507, Japan. ytogashi@kuhp.kyoto-u.ac.jp

Associated clinical trials:

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases | NCT02556593

Articles citing this

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget (2015) 0.85

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol (2014) 0.84

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report. Case Rep Oncol (2016) 0.81

Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports. Thorac Cancer (2014) 0.79

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports. Medicine (Baltimore) (2017) 0.78

Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review. Onco Targets Ther (2015) 0.77

Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet (2016) 0.76

Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med (2016) 0.76

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus (2016) 0.75

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer (2016) 0.75

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China. Iran J Public Health (2013) 0.75

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. Onco Targets Ther (2016) 0.75

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res (2016) 0.75

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer (2017) 0.75

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. Onco Targets Ther (2017) 0.75

Articles cited by this

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol (2009) 2.33

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol (2010) 1.94

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69

Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol (2010) 1.34

Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol (2009) 1.30

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol (2011) 1.24

Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer (2010) 1.17

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs (2010) 1.09

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res (2010) 1.06

High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol (2011) 1.03

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.93

Articles by these authors

Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol (2012) 7.39

Association between sleep apnea, sleep duration, and serum lipid profile in an urban, male, working population in Japan. Chest (2013) 3.23

Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer (2009) 2.35

Relationship of airway wall thickness to airway sensitivity and airway reactivity in asthma. Am J Respir Crit Care Med (2003) 2.32

A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-acupuncture trial (CAT). Arch Intern Med (2012) 2.20

Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05

Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 2.03

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82

Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80

Quantitative assessment of airway remodeling using high-resolution CT. Chest (2002) 1.79

Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest (2004) 1.77

Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest (2007) 1.66

CT scan findings of emphysema predict mortality in COPD. Chest (2010) 1.57

Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol (2009) 1.53

Effect of short-term treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med (2004) 1.53

Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52

Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med (2005) 1.52

Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med (2005) 1.52

Specific IgE response to trichophyton and asthma severity. Chest (2009) 1.49

Hot spring bath and Legionella pneumonia: an association confirmed by genomic identification. Intern Med (2002) 1.48

Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr (2010) 1.47

Corrected QT dispersion and cardiac sympathetic function in patients with obstructive sleep apnea-hypopnea syndrome. Chest (2004) 1.47

Falls in blood pressure in patients with obstructive sleep apnoea after long-term nasal continuous positive airway pressure treatment. J Hypertens (2006) 1.46

Diabetes insipidus from neurosarcoidosis: long-term follow-up for more than eight years. Intern Med (2004) 1.46

Importance of ventilator mode in long-term noninvasive positive pressure ventilation. Respir Med (2009) 1.43

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2012) 1.43

Polymorphisms of B7 (CD80 and CD86) genes do not affect disease susceptibility to sarcoidosis. Respiration (2005) 1.42

Videothoracoscopy-assisted surgical lung biopsy for interstitial lung diseases. Gen Thorac Cardiovasc Surg (2014) 1.41

Noninvasive ventilation improves the outcome of pulmonary complications after liver resection. Intern Med (2010) 1.40

Pulmonary hemorrhage induced by epileptic seizure. Heart Lung (2011) 1.39

Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol (2008) 1.38

Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37

Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35

Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol (2010) 1.34

Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. J Thorac Oncol (2010) 1.32

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32

Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest (2008) 1.28

Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol (2005) 1.28

Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med (2009) 1.28

Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer (2008) 1.27

Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med (2004) 1.27

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol (2010) 1.26

Abnormal swallowing reflex and COPD exacerbations. Chest (2009) 1.22

Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther (2006) 1.20

Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther (2009) 1.18

Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med (2006) 1.18

Role of non-invasive ventilation in managing life-threatening acute exacerbation of interstitial pneumonia. Intern Med (2010) 1.16

Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer (2008) 1.14

Optimal cutoff level of breath carbon monoxide for assessing smoking status in patients with asthma and COPD. Chest (2003) 1.11

Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest (2006) 1.10

The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol (2004) 1.08

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics (2008) 1.08

Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol (2010) 1.07

Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer (2010) 1.07

Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol (2015) 1.07

Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol (2006) 1.07

Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos (2008) 1.06

Isolation of drug-resistant pathogens does not always require use of broad-spectrum antibiotics in pneumonia. Am J Respir Crit Care Med (2014) 1.06

Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol (2007) 1.05

All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med (2006) 1.05

Diagnosis and prognosis of traumatic pulmonary psuedocysts: a review of 12 cases. Eur J Cardiothorac Surg (2006) 1.04

Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J Pharmacol Exp Ther (2008) 1.04

Longitudinal study of airway dimensions in chronic obstructive pulmonary disease using computed tomography. Respirology (2008) 1.04

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. J Thorac Oncol (2015) 1.02

Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther (2009) 1.01

Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res (2006) 1.01

Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease. Respir Res (2012) 1.01

Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment. Respirology (2008) 1.00

Cyclophosphamide-induced late-onset lung disease. Intern Med (2003) 1.00

Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Sci (2009) 1.00

Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med (2003) 1.00

Differentiation between Birt-Hogg-Dubé syndrome and lymphangioleiomyomatosis: quantitative analysis of pulmonary cysts on computed tomography of the chest in 66 females. Eur J Radiol (2011) 1.00

Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med (2011) 1.00

The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1. Biochem Pharmacol (2006) 1.00

Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J Thorac Oncol (2010) 0.99